1. Home
  2. NDLS vs KALA Comparison

NDLS vs KALA Comparison

Compare NDLS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$15.46

Market Cap

68.7M

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.64

Market Cap

21.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
KALA
Founded
1995
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
21.8M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
NDLS
KALA
Price
$15.46
$0.64
Analyst Decision
Hold
Buy
Analyst Count
1
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
31.0K
179.4K
Earning Date
05-06-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
67.39
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$0.07
52 Week High
$16.10
$20.58

Technical Indicators

Market Signals
Indicator
NDLS
KALA
Relative Strength Index (RSI) 66.30 27.04
Support Level $12.83 $0.55
Resistance Level $16.10 $0.72
Average True Range (ATR) 1.01 0.14
MACD 0.18 -0.05
Stochastic Oscillator 86.88 5.32

Price Performance

Historical Comparison
NDLS
KALA

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: